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CASE REPORT
Successful treatment of systemic lupus erythematosus with
subcutaneous immunoglobulin
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The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythe-
matosus (SLE) patients is well established. However, side effects might limit its use and lead to
the consideration of therapeutic alternatives, such as the subcutaneous formulation of
immunoglobulin, which has been used in some patients with other autoimmune diseases.
We report a case of SLE refractory to classical therapies. High-dose intravenous immuno-
globulin was effective, but gave rise to significant side effects. The patient was successfully
treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and
laboratory remission. A lower immunoglobulin dose was needed and no side effects were
observed, compared to the intravenous administration. Subcutaneous immunoglobulin
could be a better-tolerated and cost-saving therapeutic option for select SLE
patients. Lupus (2016) 25, 663–665.
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Introduction
High-dose intravenous human immunoglobulin
(IvIg) has been shown to signiﬁcantly reduce dis-
ease activity in systemic lupus erythematous (SLE)
patients,1 increase complement levels1 and to be
eﬀective in hematologic and cardiac involvement.2
It also decreases disease activity, as well as fre-
quency and severity of relapses in cutaneous lupus
patients.3 Immediate infusion-related side eﬀects
have been reported to occur in 1%–8% of IvIg per-
fusions.4 Those are probably related to immuno-
globulin peak serum concentration4 and might
limit its use in some patients.
Subcutaneous administration of human
immunoglobulin (ScIg) is well known as replace-
ment therapy in primary immunodeﬁciency, for
which lower doses are needed.5 Some authors
have also reported eﬀectiveness of ScIg therapy in
inﬂammatory myopathies and neuropathic dis-
eases.6 However, it has been proposed that
modifying immunoglobulin dose and route of
administration could change its interaction with
the immune system.6 Therefore, it is not known
whether ScIg has the same eﬀects and indications
as IvIg. In a literature review, we could not ﬁnd
any case report or series of SLE patients treated
with ScIg.
Case report
A 52-year-old Caucasian woman was diagnosed
with SLE more than 10 years ago. She presented
with extensive cutaneous involvement and histolo-
gically proven subacute cutaneous lupus and later
developed typical discoid plaques on photo-
exposed areas (Figure 1) and peripheral vasculopa-
thy lesions (Figure 2). The patient also complained
of asthenia, polyarthritis, Raynaud’s phenomenon
and sicca symptoms. Blood tests were remarkable
for positive antinuclear antibodies (1/320),
anti-double-stranded DNA (anti-dsDNA) and
anti-SSA and low C3 levels. Antiphospholipid anti-
bodies were negative. No renal or haematologic
involvement was observed during disease course.
She has been treated over the last decade with
intermittent topical corticosteroids and calcineurin
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inhibitors, low-dose systemic corticosteroids,
hydroxychloroquine and azathioprine.
Methotrexate was not tolerated because of gastro-
intestinal side eﬀects. Due to poor disease control,
namely new onset of cutaneous rash, lupus vascu-
litis and low C3 levels (0.61 g/l; laboratory refer-
ence value >0.90 g/l), scored as 12 on the Safety
of Estrogens in Lupus Erythematosus National
Assessment-Systemic Lupus Erythematosus
Disease Activity Index7 (SELENA-SLEDAI), it
was decided to associate IvIg 2 g/Kg administered
over two days every four weeks (dose per
cycle¼ 134 g). After the second cycle, a marked
clinical improvement was evident, but the patient
experienced extremely intense and incapacitating
headache, dizziness and emesis during and after
each treatment, even with a lower infusion rate
(divided over four days) and premedication with
an antihistamine. IvIg treatment was suspended
after the fourth cycle. Clinical worsening occurred
a few weeks later and it was decided to start treat-
ment with ScIg preceded by an IvIg cycle (2 g/Kg)
in order to achieve therapeutic levels. These were
afterwards maintained with 8.25 g of ScIg
(Gammanorm 0.165 g/ml), three times per week
infused at 20–30ml/hour by two portable pumps
during a two- to three-hour period. The ﬁrst three
administrations were performed at the hospital,
and treatment was continued on a home-based
self-administration thereafter. Complete clinical
response was achieved and maintained over
18 months of ScIg treatment. The patient then
decided to discontinue ScIg administration and
some weeks later a clinical ﬂare was observed,
with an increase of SELENA-SLEDAI score to
10. Restarting ScIg at the same dose did not control
disease activity. After another cycle of IvIg
followed by the same dose of ScIg, complete clinical
remission was achieved without adverse eﬀects.
The patient is currently in clinical and laboratory
remission on ScIg twice weekly (total Ig monthly
dose¼ 66 g), with a SELENA-SLEDAI score of 2
(slight hypocomplementemia – C3 0.79 g/l).
Discussion
We report the case of an SLE patient who clinically
beneﬁted from IvIg therapy, but was not able to
tolerate it due to signiﬁcant side eﬀects. Low-dose
subcutaneous immunoglobulin (approximately
100 g/month corresponding to 1.5 g/Kg/month
with further reduction to 66 g/month, equivalent
to 1 g/Kg/month) was then administered success-
fully, both in terms of eﬃcacy and tolerability.
To the best of our knowledge, ScIg for immuno-
modulatory purposes in SLE patients has not been
previously reported. Our case suggests that it may
be a valid, cost-saving therapeutic option for some
patients, maintaining eﬃcacy with a total lower
dose and favourable safety proﬁle when compared
to IvIg. The administration can be performed at
home, saving hospital associated-costs and dimin-
ishing work absenteeism.
Figure 2 Erythemato-violaceous periungual plaques.
Figure 1 Discoid lesion on the scalp.
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Moreover, serum levels of immunoglobulin are
more stable when administered subcutaneously.
Patients who are symptomatic between IvIg cycles
might beneﬁt from this pharmacokinetic property
of ScIg.
However, the dose of immunoglobulin that can
be delivered through the subcutaneous route is lim-
ited to 100 g/month, making this approach unsuit-
able for overweight patients. It also requires a
preceding IvIg cycle, with associated costs and
side eﬀects.
Similarly to what has been reported for inﬂam-
matory myopathy patients, ScIg can also be
attempted in SLE patients for whom other thera-
peutic options, such as rituximab or belimumab,
are not available or indicated. Controlled studies
are needed in order to better understand the role
of ScIg in SLE patients.
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